Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $110 price target saying the Apollo study hit "with clean safety." The analyst believes the clean safety profile differentiates Alnylam's patisiran from competitor Ionis Pharmaceuticals' (IONS) inotersen. Alnylam retains full rights to patisiran in the U.S. and Europe and is partnered with Sanofi for rest of world, Tenthoff tells investors in a research note. Alnylam shares are up 21% to $90.51 in premarket trading while Ionis is down 8% to $54.50.